Clinical guidelines from the National Institute of Health in the United States now advice against the use of hydroxychloroquine, chloroquine, Azithromycin, Tocilizumab (Actemra) and other IL-6 inhibitors, and kinase inhibitors) for treating COVID-19 [29, 30]. This evidence concerns the gene IL6 and COVID-19.